Author: Rick Doblin
Publisher: Frontiers Media SA
ISBN: 2832530230
Category : Medical
Languages : en
Pages : 120
Book Description
In 2017, the Food and Drug Administration (FDA) granted breakthrough therapy designation for 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT) for the treatment of posttraumatic stress disorder (PTSD). Six phase 2 and one phase 3 trial of a standardized MDMA-AT protocol for PTSD have consistently shown that the treatment is both safe and efficacious. MDMA-AT may hold great promise as a novel treatment for individuals who suffer from PTSD, including those with severe and treatment-resistant diagnoses. Evidence-based studies are needed to guide widespread adoption and dissemination of MDMA-AT for PTSD. The untapped therapeutic potential of MDMA-AT also warrants further investigation of indications beyond PTSD, including comorbidities that often create greater challenges in treatment and long-term efficacy. The goal of this Research Topic is to broaden the scientific literature on MDMA-AT across disciplines. Specifically, studies are needed to provide (i) guidance on the dissemination of MDMA-AT for PTSD, (ii) future research directions for MDMA-AT including investigation of other indications, and (iii) theoretical frameworks and models of biological mechanisms to explain the therapeutic effects of MDMA-AT.